Pharos iBio Co., Ltd.

A388870

KR7388870008

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 23:00:00 27/06/2024 BST			5-day change	1st Jan Change
10,750 ^KRW	+1.22%		-9.36%	-27.51%

2023	Pharos Therapeutics INC announced that it has received KRW 1.3523 billion in funding from Pharos iBio Co., Ltd.	CI
2023	Pharos Therapeutics INC announced that it expects to receive KRW 1.3523 billion in funding from Pharos iBio Co., Ltd.	CI

Pharos Therapeutics INC announced that it has received KRW 1.3523 billion in funding from Pharos iBio Co., Ltd.

November 31, 2023

On November 1, 2023, Pharos Therapeutics INC closed the transaction.

Latest news about Pharos iBio Co., Ltd.

Pharos Therapeutics INC announced that it has received KRW 1.3523 billion in funding from Pharos iBio Co., Ltd.	10-31	CI
Pharos Therapeutics INC announced that it expects to receive KRW 1.3523 billion in funding from Pharos iBio Co., Ltd.	26/10/23	CI

Pharos IBio Co Ltd is a Korea-based company principally engaged in the research and development of new drugs. The Company principally engaged in the research and development of new drugs such as treatments for rare and intractable diseases. The Company is engaged in the development of treatments for rare and intractable diseases such as relapse-refractory ovarian cancer, acute myeloid leukemia, triple-negative breast cancer, recurrent acute myeloid leukemia as well as others.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PHAROS IBIO CO., LTD.	-27.51%	101M
VERTEX PHARMACEUTICALS INCORPORATED	+15.20%	121B
REGENERON PHARMACEUTICALS, INC.	+19.67%	113B
ARGENX SE	+17.03%	26.02B
BIONTECH SE	-23.86%	19.39B
GENMAB A/S	-19.40%	15.91B
BEIGENE, LTD.	-20.90%	15.09B
WUXI APPTEC CO., LTD.	-46.14%	15.06B
SAREPTA THERAPEUTICS, INC.	+63.85%	14.93B
NEUROCRINE BIOSCIENCES, INC.	+4.49%	13.85B